Company intelligence / Profile preview

Unither Bioengineering

Silver Spring, Maryland, United Statescorporateresponsibility.unither.com ↗

Ownership: Private
Employees: ~1168
Development stage: Commercial

Overview

The company has FDA-approved drugs including Remodulin (a prostacyclin vasodilator for PAH). In 2022, they conducted the first pig-to-human heart transplant in conjunction with the University of Maryland Medical Center, though the recipient died two months later[3].

Therapeutic areas: CardiovascularInfectious Diseases
Modalities: PharmaceuticalsOrgan transplantation technologiesXenotransplantation
Industry: Biotech

Drug pipeline

1 asset

UKidney

IND

Indications: Organ transplantation

Partnerships

Eli Lilly and CompanyDEKA Research & DevelopmentMannKind CorporationNational Cancer InstituteUniversity of Maryland Medical Center

Beyond the preview

Go deeper on Unither Bioengineering.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unither Bioengineering.

Explore the full profile